CL2013001707A1 - Comprimido de liberacion controlada no hinchable para administracion oral de un principio activo que esta en un sistema matricial polimerico erosionable y de liberacion por difusion formado por polimero retardante y copolimero formador de matriz; metodo para preparar una composicion farmaceutica; uso para preparar un medicamento. - Google Patents

Comprimido de liberacion controlada no hinchable para administracion oral de un principio activo que esta en un sistema matricial polimerico erosionable y de liberacion por difusion formado por polimero retardante y copolimero formador de matriz; metodo para preparar una composicion farmaceutica; uso para preparar un medicamento.

Info

Publication number
CL2013001707A1
CL2013001707A1 CL2013001707A CL2013001707A CL2013001707A1 CL 2013001707 A1 CL2013001707 A1 CL 2013001707A1 CL 2013001707 A CL2013001707 A CL 2013001707A CL 2013001707 A CL2013001707 A CL 2013001707A CL 2013001707 A1 CL2013001707 A1 CL 2013001707A1
Authority
CL
Chile
Prior art keywords
matrix
diffusion
medicine
prepare
preparing
Prior art date
Application number
CL2013001707A
Other languages
English (en)
Inventor
Arroyo Hector Senosiain
Paniagua Maria Angelica Arzola
Hernandez Gustavo Barranco
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001707(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of CL2013001707A1 publication Critical patent/CL2013001707A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013001707A 2010-12-17 2013-06-13 Comprimido de liberacion controlada no hinchable para administracion oral de un principio activo que esta en un sistema matricial polimerico erosionable y de liberacion por difusion formado por polimero retardante y copolimero formador de matriz; metodo para preparar una composicion farmaceutica; uso para preparar un medicamento. CL2013001707A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010014153A MX2010014153A (es) 2010-12-17 2010-12-17 Comprimido farmaceutico de liberacion controlada para administracion oral.

Publications (1)

Publication Number Publication Date
CL2013001707A1 true CL2013001707A1 (es) 2014-01-10

Family

ID=46245166

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001707A CL2013001707A1 (es) 2010-12-17 2013-06-13 Comprimido de liberacion controlada no hinchable para administracion oral de un principio activo que esta en un sistema matricial polimerico erosionable y de liberacion por difusion formado por polimero retardante y copolimero formador de matriz; metodo para preparar una composicion farmaceutica; uso para preparar un medicamento.

Country Status (11)

Country Link
BR (1) BR112013014963A2 (es)
CL (1) CL2013001707A1 (es)
CO (1) CO6721021A2 (es)
CR (1) CR20130288A (es)
DO (1) DOP2013000136A (es)
EC (1) ECSP13012766A (es)
GT (1) GT201300154A (es)
MX (1) MX2010014153A (es)
PE (1) PE20140675A1 (es)
RU (1) RU2603469C2 (es)
WO (1) WO2012080984A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016058813A1 (en) 2014-10-16 2016-04-21 Koninklijke Philips N.V. Aligning a patient within an mr scanner

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2002358270A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same

Also Published As

Publication number Publication date
CR20130288A (es) 2013-08-13
DOP2013000136A (es) 2013-10-15
PE20140675A1 (es) 2014-06-25
RU2603469C2 (ru) 2016-11-27
BR112013014963A2 (pt) 2016-09-13
WO2012080984A3 (es) 2012-08-16
GT201300154A (es) 2014-05-07
ECSP13012766A (es) 2013-09-30
RU2013127408A (ru) 2015-01-27
MX2010014153A (es) 2012-06-18
CO6721021A2 (es) 2013-07-31
WO2012080984A2 (es) 2012-06-21

Similar Documents

Publication Publication Date Title
CL2013000424A1 (es) Forma de dosificacion farmaceutica resistente al rompimiento que comprende a) un ingrediente farmacologicamente activo, b) un polimero, c) un oxido de polialquileno, donde a) esta presente en una matriz de liberacion controlada que comprende b) y c).
CL2009000557A1 (es) Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos
CL2013003161A1 (es) Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion.
CL2014001029A1 (es) Forma de dosificacion farmaceutica solida oral de liberacion extendida que comprende una formulacion matricial que comprende un agente activo en forma de comprimido o multiparticulado; agente activo es un analgesico opioide; y uso en el tratamiento del dolor. (div. sol. 499-2012).
WO2008146178A3 (en) A novel tablet dosage form
AR084865A1 (es) Preparacion de desintegracion rapida, comprimido dispersable por via oral
CL2013001942A1 (es) Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso.
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
WO2011115969A3 (en) Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
BR112013029199A2 (pt) sistema de distribuição de fármacos, dispositivo de distribuição de dois fármacos, método para preparar o mesmo, comprimido para administração sublingual de um ingrediente ativo, e, método para a administração de um ingrediente ativo a um indivíduo
WO2010127205A3 (en) Fixed dose drug combination formulations
PH12014501408A1 (en) Immediate release multi unit pellet system
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
BR112013012100A2 (pt) composição ou formulação farmacêutica adaptada para administração oral em forma de comprimido, comprimido revestido ou cápsula na prevenção ou tratamento de distúrbios intestinais, processo para preparar a composição ou formulação farmacêutica e uso da composição ou formulação farmacêutica
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
CL2013001707A1 (es) Comprimido de liberacion controlada no hinchable para administracion oral de un principio activo que esta en un sistema matricial polimerico erosionable y de liberacion por difusion formado por polimero retardante y copolimero formador de matriz; metodo para preparar una composicion farmaceutica; uso para preparar un medicamento.
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
WO2012068076A3 (en) Pharmaceutical formulations containing soluble drugs
CO6390098A2 (es) Formulaciones de desintegración rapida pre-compactadas de compuestos con baja biodisponibilidad oral.